MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, is pleased to announce the publication of “Clinical Experience Using Cortoss for Treating Vertebral Compression Fractures with Vertebroplasty and Kyphoplasty” in the September 15, 2010 edition of Spine. The article presents the clinical data from two FDA-approved investigational device exemption (IDE) pilot studies sponsored by Orthovita. These multi-center, prospective trials assessed the feasibility and clinical outcomes of Cortoss™ Bone Augmentation Material using the two different vertebral augmentation techniques of vertebroplasty and kyphoplasty.
